Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:70:154053.
doi: 10.1016/j.jcrc.2022.154053. Epub 2022 May 12.

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Harry Zacharias  1 , Ritwik Mungara  1 , Andrew Peter Wilson  2 , Mervyn Singer  1 , Nishkantha Arulkumaran  3
Affiliations

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19

Harry Zacharias et al. J Crit Care. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no competing interest to declare.

Figures

Fig. 1
Fig. 1
CRP trajectory of patients receiving dexamethasone alone or dexamethasone with Tocilizumab.
Fig. 2
Fig. 2
Trajectory of ferritin, B-type natriuretic peptide (BNP), D-dimer, neutrophils, lymphocytes, and neutrophil: lymphocyte ratio (NLR) among patients receiving dexamethasone with Tocilizumab.
See this image and copyright information in PMC

References

    1. Manson J.J., Crooks C., Naja M., et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–e602. - PMC - PubMed
    1. Group RC Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
    1. Group RC, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed
    1. Kooistra E.J., van Berkel M., van Kempen N.F., et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 2021;25:281. - PMC - PubMed
    1. Zanella A., Florio G., Antonelli M., et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021:1–14. - PMC - PubMed

Publication types